Archives of Hepatitis Researchhttps://www.peertechz.com/journals/archives-of-hepatitis-research
A Peertechz Open Access Journalen-usOccult Hepatitis B Virus infection in a cohort of patients with chronic Hepatitis C26 Jul, 2019https://www.peertechz.com/articles/AHR-5-122.php
Introduction: The prevalence of occult hepatitis B, defi ned by absence of HBsAg and HBV DNA,
ranges widely in patients with hepatitis C. This may infl uence the treatment of hepatitis C and the severity
of liver diseaseExperience with Hepatitis B Viral load Testing in Jharkhand29 Apr, 2019https://www.peertechz.com/articles/AHR-5-121.php
Background: Quantification of the viral burden is an important laboratory tool in the management of hepatitis B virus (HBV)-infected patients. However, widespread use of assays is still hampered by the high cost. Treatment reduces viral load to undetectable levels. HBV infected patients tend to have high HBV DNA levels, and severe liver disease.
Objectives: This study was carried out to determine the pattern of HBV viral load levels of patients in Jharkhand.
Hepatitis B treatment in Light of Natural sources13 Mar, 2019https://www.peertechz.com/articles/AHR-5-120.php
Hepatitis B virus causes acute and chronic inflammation of liver which may leads to hepatocellular carcinoma, cirrhosis and death. Chronic hepatitis B is usually accompanied by the presence of detectable hepatitis B surface antigen (HBsAg) in the blood for greater than 6 months. The presence of hepatitis B envelope antigen (HBeAg) is related to higher rates of viral replication leading to more infection. Objective: Currently vaccination for prevention of hepatitis B is present and its treatment includes pegylated interferon α, lamivudine, telbivudine and entecavir (nucleoside analogues) and adefovir (nucleotide analogues). This treatment is partially effective and has signifi­cant dose dependent side effects and resistance after long term use. Hence, there is a need to develop new more safe and potent agents against hepatitis B from medicinal plants. This review illustrates the description of medicinal plants, family, their active ingredients, parts and extracts used to treat hepatitis B by their mechanisms. The pharmaceutical companies are striving to discover appropriate alternative and natural inhibitors of targeting different steps of HBV life cycle, because single plant contains an invaluable number of active ingredients which could help in the manufacture of pharmaceutical grade proteins and has wide spectrum of antiviral activity. However, information of antiviral activity of plants is still inadequate. The correlation between serum cytokine levels and liver cirrhosis in chronic hepatitis B patients: A meta-analysis25 Oct, 2018https://www.peertechz.com/articles/AHR-4-119.php
Background: The harm of liver cirrhosis (LC) is serious, and the development of LC is primarily resulted from chronic hepatitis B virus (HBV) in high-risk such as China and Africa and chronic hepatitis C virus (HCV) in developed areas such as United States. Currently, there were 360 million chronic HBV-infected people on a global scale, and 30 million chronic hepatitis B (CHB) patients in China. In general, cytokines can regulate immune responses or contribute to deleterious tissue injury. However, the effects of these cytokines reported were controversial. Therefore, we executed a meta-analysis evaluating whether these cytokines can change the development risk of LC.
Active Navigation in a Hepatitis B Program: Screening, Vaccination and Patient Assistance for Asian Americans in Michigan20 Aug, 2018https://www.peertechz.com/articles/AHR-4-118.php
Background: Hepatitis B (HBV) is one of the greatest health disparities among Asian Americans. A team of volunteers in Southeast Michigan has studied HBV among Asian Americans in Michigan for 10 years. The study looked at prevalence of HBV among Asian Americans in Michigan, and the effectiveness of programs that included screening, vaccination and patient navigation.
Vitamin K: A potential Liver Cancer treatment way26 Sep, 2017https://www.peertechz.com/articles/AHR-3-117.php
A review on different vitamin K1-3 effects on hepatocellular cancer and their tumour cell biology mechanism indicate possible synergistic treatment strategies.Hepatic histological comparison between Acute Self-limiting Hepatitis A and Hepatitis E21 Jun, 2017https://www.peertechz.com/articles/AHR-3-116.php
Background: Histological findings of the liver in acute liver injury are basically affected by degree of liver damage. However, the differences in liver histology between acute self-limiting hepatitis A (AH-A) and hepatitis E (AH-E) have not yet been clarified. This study aimed to clarify the differences in histological findings of the liver between AH-A and AH-E.Accidentally discovered Portal Vein Thrombosis before Splenectomy due to Hypersplenism - The role of Thrombogenic Genes Polymorphisms19 Jun, 2017https://www.peertechz.com/articles/AHR-3-115.php
Portal vein thrombosis in patients with liver cirrhosis may be due neoplastic growth invading portal vein or due to non-neoplastic causes. The indications for treating PVT in cirrhotic individuals are difficult to be established but at least are of great benefit in acute PVT. Investigating the cause of portal vein thrombosis in cirrhotic patient prepared for splenectomy including virology and immune markers, AFP, triphasic CT.Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review12 Jun, 2017https://www.peertechz.com/articles/AHR-3-114.php
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of fatty liver, characterized by the accumulation of fat in the hepatocytes in the absence of alcohol consumption. The spectrum of this disease ranges from steatosis to hepatitis and fi nally cirrhosis and hepatocellular carcinoma.Constipation during Entecavir treatment in Chronic Hepatitis B patients: Two Cases Reports29 May, 2017https://www.peertechz.com/articles/AHR-3-113.php
Entecavir (ETV) is an oral nucleoside analog inhibitor of hepatitis B virus (HBV) DNA polymerase, which
is widely used in patients with chronic hepatitis B (CHB). Despite the excellent safety data of this agent,
the adverse events of headache, diarrhea, nausea and vomiting are recorded in the drug instruction of ETV.Here we report two CHB patients with ETV-associated constipation in whom symptom fully disappeared following ETV withdrawal.Sarcoidosis-Lymphoma Syndrome presenting by severe Cholestatic Hepatitis18 May, 2017https://www.peertechz.com/articles/AHR-3-112.php
Severe cholestatic hepatitis is an uncommon presentation of either sarcoidosis or Hodgkin
lymphoma. Sarcoidosis lymphoma syndrome is a rare disorder with sarcoidosis heralding the onset of
lymphoma. Here we report a case of coexisting sarcoidosis-Hodgkin’s lymphoma syndrome presenting
with severe cholestatic hepatitis.Hepatitis E: New Clinical and Public Health Problem on the Western World? Review31 Mar, 2017https://www.peertechz.com/articles/AHR-3-111.php
Until recently, the occurrence of Hepatitis E in the western hemisphere did not amount to a clinical concern, due to its benign and usually sub-clinical evolution, as opposed to Asiaand Africa, where large epidemies with high levels of lethality occur.Relative and combined Effects of Ethanol and Hepatitis C Virus Infection on Serum Interleukin-17 Levels20 Mar, 2017https://www.peertechz.com/articles/AHR-3-110.php
Background: Interleukin-17 (IL-17) is involved in neutrophil recruitment and may contribute to the
progression from fatty liver to steatohepatitis.Hepatitis E: Diagnostic and Therapeutic Challenges07 Mar, 2017https://www.peertechz.com/articles/AHR-3-109.php
Hepatitis E virus (HEV) is a globally important water and
foodborne pathogen of acute and chronic hepatitis E [1,2]. HEV
infection may be symptomatic or asymptomatic that has
affected about one-third of world population with a case fatality
rate of 1-2%, including 20-30% of infected pregnant women
[3-5].Liver Specific Serum Micro RNA122 as a Prognostic Marker in Egyptian Patients with Liver Cirrhosis30 Jan, 2017https://www.peertechz.com/articles/AHR-3-108.php
Introduction: Recent research has shown that microRNAs (miRNA) are emerging as important
regulators of cellular differentiation. The miR-122 accounts for approximately 70% of all miRNAs in the
liver so its presence in the serum is highly indicative of liver processes.The Potential of Liver Fibrosis Indexes/Scores for the Screening of Cryptic Liver Fibrosis in Patients with NASH Risk Factors: A Case Report27 Jan, 2017https://www.peertechz.com/articles/AHR-3-107.php
The unintentional discovery of cirrhosis in a patient with prostate cancer lead us to enquire if some of
the indexes/scored designed for the evaluation of liver fi brosis/cirrhosis, in Chronic Hepatitis C patients,
could have helped us in the detection of incipient liver fi brosis, and its follow up, in this patient.Serum YKL-40 (Chitinase-3-Like Protein 1) Compared to APRI and FIB-4 in Predicting Liver Fibrosis in Children with Chronic Hepatitis C30 Dec, 2016https://www.peertechz.com/articles/AHR-2-106.php
Background: Liver fibrosis is a critical factor for the treatment policy and its outcome in chronic hepatitis C virus (HCV) infection. Although liver biopsy represents the gold standard for evaluating fibrosis, it remains an invasive procedure with inherent risks. Occupational Hazard (Hepatitis B & C)21 Nov, 2016https://www.peertechz.com/articles/AHR-2-105.php
Hepatitis B and C are considered as an important health hazard among health care workers (HCWs). These blood borne infections can be transmitted either from HCW to a patient or vice-versa. Both viruses are known to cause hepatitis, cirrhosis and hepatocellular carcinoma. Non-Alcoholic Fatty Liver Disease Frequency among Healthy Blood Donors in the West of Iran30 Aug, 2016https://www.peertechz.com/articles/AHR-2-104.php
Objectives: To investigate the prevalence of NAFLD as well as the determination of associated metabolic abnormalities in Iranian blood donors. The aim of this study was to review cases of non-alcoholic fatty liver disease and to determine the prevalence of non-alcoholic fatty liver disease as a cause of elevated alanine aminotransferase in healthy blood donors and also assess risk factors of NAFLD such as BMI and correlation with metabolic syndrome in these subjectsManagement of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**30 Dec, 2015https://www.peertechz.com/articles/AHR-1-103.php
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to interferon (IFN). IFN-free treatments are now considered elective drugs for patients with chronic HCV. More than 90% of patients infected with HCV genotype 1 or 4 (fewer with other genotypes) show sustained virological response, when treated with sofosbuvir combined with simeprevir, daclatasvir or ledipasvir, or by the combination of paritaprevir with ritonavir, ombitasvir and dasabuvir, with or without ribavirin. Association of the Treatment Induced Clearance of Hepatitis C Virus Infection with the IL28B Gene Polymorphisms28 Dec, 2015https://www.peertechz.com/articles/AHR-1-102.php
Background: It has been shown that single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) gene were associated with sustained viral response following standard treatment of hepatitis C virus infection.
Aim: The aim of the study was to evaluate the association between the SNPs near the IL28B gene and the response to the treatment of chronic hepatitis C. Current Trends of Combination Therapy in Chronic Hepatitis B Management in China28 Aug, 2015https://www.peertechz.com/articles/AHR-1-101.php
In the past decade, five oral nucleos(t)ide analogs and two formulations of pegylated interferon alpha have been approved for the treatment of chronic hepatitis B (CHB). Due to low personal income and inadequate health care system, low-to-moderate genetic barrier antiviral drugs are still widely used in China, which brings increased suboptimal response, viral relapse and resistance in real-life clinical practice.